BeOne Medicines Ltd. (ONC)
BeOne Medicines Ltd. (ONC) from its SEC filings: 2025 revenue $5.3 billion (+40% vs the year before), net margin 5%, free cash flow $941.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $5.3 billion |
| Revenue growth | +40% |
| Net income | $286.9 million |
| Net margin | 5.4% |
| Free cash flow | $941.7 million |
| Diluted EPS | $0.19 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +30% |
| Cash | $5.1 billion |
| Long-term debt | $1.2 billion |
| Share count, 1 year | +3% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.